Publication | Open Access

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

Breast OncologyMedicineClinical TrialsPathologyBreast CancerCancer TreatmentOncologyRadiation OncologyUpdated ResultsMolecular OncologyHealth Sciences